Vivos Therapeutics chairman and CEO Kirk Huntsman joins Natalie Stoberman from the Proactive studios to discuss the company’s first-quarter financial and operational highlights.
Huntsman says the main highlight of comes from acquisition of certain US and international patents, product rights, and other miscellaneous intellectual property from Advanced Facialdontics to fill gaps in Vivos’ product line.
Huntsman also shares how the company’s cost reduction efforts, distribution agreements, and the potential for further growth have been executed while the company continues to reach more patients and providers.
#ProactiveInvestors #VivosTherapeutics #SleepTreatment #Q1Highlights #ObstructiveSleepApnea #SleepApneaTreatment #HealthcareInnovation #MedicalTechnology #BruxismTreatment #TMDRelief #MigraineHeadacheSolution #FDAclearance #SleepHealth #HealthTech #SleepDisorders #DentalCare #CPAPAlternative #PatientCare #MedicalResearch #SleepWellness #HealthandWellness #SleepSolutions #DMEcompanies #HealthcareIndustry #InnovativeTherapies #SleepMedicine #HealthcareUpdates #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
source